Download PDF
Hamostaseologie
DOI: 10.1055/a-2780-3616
Original Article

Tramadol and Its Influence on Platelet Function — An Ex Vivo Study

Authors

  • Philipp Zoidl 

    1   Department of Anesthesiology and Intensive Care Medicine, Medical University of Graz, Graz, Austria (Ringgold ID: RIN31475)

  • Helmar Bornemann-Cimenti

    1   Department of Anesthesiology and Intensive Care Medicine, Medical University of Graz, Graz, Austria (Ringgold ID: RIN31475)

  • Michael Eichinger

    1   Department of Anesthesiology and Intensive Care Medicine, Medical University of Graz, Graz, Austria (Ringgold ID: RIN31475)

  • Michael Eichlseder

    1   Department of Anesthesiology and Intensive Care Medicine, Medical University of Graz, Graz, Austria (Ringgold ID: RIN31475)

  • Lioba Heuschneider

    1   Department of Anesthesiology and Intensive Care Medicine, Medical University of Graz, Graz, Austria (Ringgold ID: RIN31475)

  • Nikolaus Schreiber

    1   Department of Anesthesiology and Intensive Care Medicine, Medical University of Graz, Graz, Austria (Ringgold ID: RIN31475)

  • Paul Zajic

    1   Department of Anesthesiology and Intensive Care Medicine, Medical University of Graz, Graz, Austria (Ringgold ID: RIN31475)

  • Gudrun Rumpold-Seitinger

    1   Department of Anesthesiology and Intensive Care Medicine, Medical University of Graz, Graz, Austria (Ringgold ID: RIN31475)

  • Florian Prüller

    2   Clinical Institute for Medical and Chemical Laboratory Diagnostics (KIMCL), Medizinische Universität Graz, Graz, Austria (Ringgold ID: RIN31475)

  • Gabriel Honnef

    1   Department of Anesthesiology and Intensive Care Medicine, Medical University of Graz, Graz, Austria (Ringgold ID: RIN31475)
Further Information
Also available at
  Permissions and Reprints

Abstract

Tramadol, a weak μ-opioid receptor agonist and a widely used analgesic, also inhibits serotonin and norepinephrine reuptake, which could potentially influence platelet function. While the bleeding risk of selective serotonin reuptake inhibitors is well documented, the impact of tramadol on platelet aggregation, despite its widespread use, remains underexplored. Therefore, this study aims to elucidate tramadol’s effect on platelet function. This single-center laboratory study involved healthy volunteers at the Medical University of Graz, Austria. Platelet function was assessed using light transmission aggregometry following the addition of tramadol in increasing concentrations (0, 500, 1500, 4500, and 9000 ng/mL) to blood samples. Baseline and post-tramadol-addition platelet aggregation was measured using adenosine diphosphate-induced (ADP), ristocetin-induced, and thrombin-receptor activating peptide-induced (TRAM) aggregation. Statistical analysis employed the Friedman test. Seven healthy volunteers could be included in the final analysis. Platelet aggregation was assessed after ex vivo addition of tramadol (500–9000 ng/mL). No significant differences in aggregation percentages were observed between tramadol concentrations and baseline inducing activation with ADP, ristocetin, or TRAP. These findings suggest that tramadol, at therapeutic and supratherapeutic concentrations, does not significantly impair platelet function in most individuals. This supports the general safety profile of tramadol regarding platelet aggregation.

Tramadol appears safe concerning platelet function. Further research with larger cohorts is warranted to confirm these results and investigate potential interindividual variability in response to tramadol.

Keywords

Tramadol - Platelet aggregation - Analgesics - Opioids - Serotonin agents

Data Sharing Statement

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.




Publication History

Received: 12 May 2025

Accepted after revision: 30 December 2025

Article published online:
12 February 2026

© 2026. Thieme. All rights reserved.

Georg Thieme Verlag KG
Oswald-Hesse-Straße 50, 70469 Stuttgart, Germany